Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 234-717-7 | CAS number: 12027-06-4
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 980
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- Study performed before OECD 401 development
- Deviations:
- not applicable
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- Ammonium iodide
- EC Number:
- 234-717-7
- EC Name:
- Ammonium iodide
- Cas Number:
- 12027-06-4
- Molecular formula:
- H4IN
- IUPAC Name:
- ammonium iodide
- Test material form:
- solid
Constituent 1
- Specific details on test material used for the study:
- Data available only for potassium iodide (similar inorganic iodide)
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Remarks:
- 10%
- Doses:
- 2000, 2500, 2800, 3200, 3600, and 4000 mg/kg body weight
- No. of animals per sex per dose:
- 10 male and 10 female individuals per dose, including control group
- Control animals:
- yes
Results and discussion
Effect levelsopen allclose all
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 3 118 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 2 931 - <= 3 318
- Remarks on result:
- other: 1 day after administration
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 2 779 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 2 610 - <= 2 959
- Remarks on result:
- other: 7+14 after administration
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 3 129 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 2 874 - <= 3 408
- Remarks on result:
- other: 7 + 14 days after administration
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 2 489 - 2 696 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 2 289 - <= 2 696
- Remarks on result:
- other: 7 + 14 days after admonistration
Applicant's summary and conclusion
- Interpretation of results:
- study cannot be used for classification
- Conclusions:
- Data available only for potassium iodide (similar inorganic iodide)
The results shows the 24 hour LD50 of iodide to rat was 3118 mg/kg bw which is higher than the criteria of 2000 mg/kg bw under the Regulation (EC) No. 1272/2008. - Executive summary:
Data available only for potassium iodide (similar inorganic iodide)
In one company study (A. Hausner, G. Weise, and A. Hofmann, 1980), the effects of iodide were studied in male and female Wistar rats. In the test, 10 male and 10 female in each dose and control groups were administrated with potassium iodide for 14 days at dose of 0 (control), 2000, 2500, 2800 3200, 3600, and 4000 mg/kg body weight mg/kg bw respectively. The key value of LD50 was calculated by Probit-analysis (Fink und Hund 1965).The 24 hour LD50 of iodide to rats (male/female) was calculated to be 3118 mg/kg bw under test conditions.
7-14 days LD50 of iodide to rats (male/female) was calculated to be 2779 mg/kg bw under test conditions.
Besides of the results on mortality, some other non-lethal effects were also investigated. 5-15 min after application first symptoms of poisoning was observed. The main symptoms were: lethargy, exophthalmus, stagger, dypsnoe, ruffled fur. The symptoms could be observed in all dosing in the first 72h. Staggering was observed up to 5 days. The 2000mg/kg bw group showed no symptoms beside stagger after 48h. A part of the 2500mg/kg bw, 2800mg/kg bw and 3200mg/kg bw groups showed ventral position and paralysis of extremities in the period from 1-24h. Apart from stagger this group showed no symptoms after 72h.
The 3600mg/kg bw group showed ventral position and paralysis of extremities in the period from 1-24h. Slight symptoms of lethargy and dyspnoe could be observed up to 5 days after administration. Slight stagger could be observed up to 7 days after administration.
The 4000mg/kg bw group showed ventral position and paralysis of extremities in the period from 1-24h. Ventral position could be be observed temporarily up to 5 days. Symptoms of lethargy and dyspnoe could be observed up to 5 days after administration.
All surviving animals showed no symptoms after 7 days.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
